Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

2.

Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies.

Ho N, Li A, Li S, Zhang H.

Pharmaceuticals (Basel). 2012 Jul 25;5(8):779-801. doi: 10.3390/ph5080779.

3.

Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Barrott JJ, Hughes PF, Osada T, Yang XY, Hartman ZC, Loiselle DR, Spector NL, Neckers L, Rajaram N, Hu F, Ramanujam N, Vaidyanathan G, Zalutsky MR, Lyerly HK, Haystead TA.

Chem Biol. 2013 Sep 19;20(9):1187-97. doi: 10.1016/j.chembiol.2013.08.004.

4.

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E.

Blood. 2013 Oct 17;122(16):2837-47. doi: 10.1182/blood-2013-01-479972.

5.

A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.

Gopalakrishnan R, Matta H, Chaudhary PM.

Clin Cancer Res. 2013 Sep 15;19(18):5016-26. doi: 10.1158/1078-0432.CCR-12-3510.

6.

The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.

Lisi L, McGuire S, Sharp A, Chiosis G, Navarra P, Feinstein DL, Dello Russo C.

J Neuroimmunol. 2013 Feb 15;255(1-2):1-7. doi: 10.1016/j.jneuroim.2012.10.008.

7.

Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.

Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, Chiosis G, Massoud TF, Paulmurugan R, Gambhir SS.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):E2476-85. doi: 10.1073/pnas.1205459109.

8.

Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation.

Bohonowych JE, Peng S, Gopal U, Hance MW, Wing SB, Argraves KM, Lundgren K, Isaacs JS.

BMC Cancer. 2011 Dec 15;11:520. doi: 10.1186/1471-2407-11-520.

9.

Efficient Synthesis of a Novel Resorcyclide as Anticancer Agent Based on Hsp90 Inhibition.

Lei X, Danishefsky SJ.

Adv Synth Catal. 2008 Aug 4;350(11-12):1677-1681.

10.

Conformational dynamics of the molecular chaperone Hsp90.

Krukenberg KA, Street TO, Lavery LA, Agard DA.

Q Rev Biophys. 2011 May;44(2):229-55. doi: 10.1017/S0033583510000314. Review.

11.

A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases.

Guarnieri MT, Blagg BS, Zhao R.

Assay Drug Dev Technol. 2011 Apr;9(2):174-83. doi: 10.1089/adt.2010.0289.

12.

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A.

Nat Med. 2009 Dec;15(12):1369-76. doi: 10.1038/nm.2059.

13.

Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.

Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS, Hewitt SM, Khan J.

Cancer Biol Ther. 2009 Dec;8(24):2386-95.

14.

Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide.

Krukenberg KA, Böttcher UM, Southworth DR, Agard DA.

Protein Sci. 2009 Sep;18(9):1815-27. doi: 10.1002/pro.191.

15.

pH-dependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation.

Krukenberg KA, Southworth DR, Street TO, Agard DA.

J Mol Biol. 2009 Jul 10;390(2):278-91. doi: 10.1016/j.jmb.2009.04.080.

16.

Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90.

Krukenberg KA, Förster F, Rice LM, Sali A, Agard DA.

Structure. 2008 May;16(5):755-65. doi: 10.1016/j.str.2008.01.021.

17.

Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.

Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS.

Cancer Res. 2008 Jan 1;68(1):216-26. doi: 10.1158/0008-5472.CAN-07-2268.

Items per page

Supplemental Content

Support Center